树突状细胞-细胞因子诱导的杀伤细胞联合放化疗在局部晚期非小细胞肺癌中的疗效观察  

Efficacy of DC-CIK combined with chemoradiotherapy in locally advanced non-small cell lung cancer

作　　者：吴文清[1] 柯传庆[1] 江龙委 吴嘉[1] 孙玲[1] WU Wenqing;KE Chuanqing;JIANG Longwei;WU Jia;SUN Ling(Department of Oncology,the 908th Hospital of the Joint Logistics Support Force,PLA,Nanchang 330000,Jiangxi,China;Department of Oncology,Qinhuai Medical Treatment Area,General Hospital of Eastern Theater Command,PLA,Nanjing 210002,Jiangsu,China)

机构地区：[1]中国人民解放军联勤保障部队第九○八医院肿瘤科,南昌330000 [2]东部战区总医院秦淮医疗区肿瘤科,南京210002

出　　处：《医学研究与战创伤救治》2025年第1期67-72,共6页Journal of Medical Research & Combat Trauma Care

摘　　要：目的观察树突状细胞-细胞因子诱导的杀伤细胞(DC-CIK)联合放化疗治疗非小细胞肺癌的疗效。方法回顾性分析2020年10月至2021年9月东部战区总医院秦淮医疗区肿瘤科收治的局部晚期非小细胞肺癌患者60例,其中行DCCIK联合放化疗治疗的30例患者为联合组,同期接受单纯放化疗治疗的30例患者为对照组,统计患者的临床资料及治疗前后1,25-二羟维生素D3、T细胞亚群的变化,分析1,25-二羟维生素D3及T细胞亚群与治疗疗效的关系。结果治疗后联合组客观缓解率和疾病控制率均高于对照组(80%vs 76.7%、93.3%vs 90%),但差异无统计学意义(P>0.05);联合组患者中位无疾病进展生存时间(PFS)、中位总生存期(OS)均高于对照组(14.6个月vs 9.3个月、25.8个月vs 18.5个月),差异均有统计学意义(P<0.05);联合组患者治疗后CD3^(+)、CD4^(+)、CD8^(+)、CD56^(+)T细胞水平及CD4^(+)/CD8^(+)比值均较治疗前升高,对照组治疗后上述细胞水平均下降,联合组治疗后的淋巴细胞水平均高于对照组,其中CD3^(+)、CD4^(+)、CD4^(+)/CD8^(+)组间差异有统计学意义(P<0.05);患者治疗前后1,25-二羟维生素D3变化及2组间差异无统计学意义(P>0.05)。2组治疗过程中无严重不良反应发生。结论DC-CIK联合放化疗治疗局部晚期非小细胞肺癌能提高患者PFS和OS,是安全有效的,能达到更好的临床获益并改善免疫功能。Objective The efficacy of DC-CIK and chemoradiotherapy in non-small cell lung cancer was observed.Methods A retrospective analysis of 60 patients with locally advancednon-small cell lung cancer admitted from October 2020 to September 2021,including 30 patients treated with chemotherapy combined with DC-CIK in the observation group,and 30 patients with radiotherapy combined with chemotherapy in the control group.The clinical data,the changes of 1,25-dihydroxyvitamin D3 and T cell subsets before and aftertreatment,and the relationship between 1,25-dihydroxyvitaminD3 and T cell subsets and treatment efficacy were analyzed.Results The objective response rates in the observed and control groups were 80%and 76.7%,respectively(P>0.05).while the disease control rates of 93.3%and 90%,respectively(P>0.05).The median PFS and median OS in the observation group were higher than those in the control group(14.6 months vs 9.3 months,25.8 months vs 18.5 months,P<0.05).In the observation group,CD3^(+),CD4^(+),CD8^(+),CD4^(+)/CD8^(+)and CD56^(+)T cells levels increased after treatment compared to baseline levels.The above cell levels were all decreased after treatment in the control group.The post-treatment lymphocyte levels in the observation group were higher than those in the control group,with statistically significant differences observed in CD3^(+),CD4^(+),and CD4^(+)/CD8^(+)levels(P<0.05).No significant differences were found in 1,25-dihydroxyvitamin D3 levels before and after treatment between the two groups(P>0.05).No serious adverse reactions occurred during the treatment process.Conclusion The combination of DC-CIK with radiotherapy and chemotherapy for locally advanced non-small cell lung cancer can improve PFS and OS,is safe and effective,and provide better clinical benefits and improving immune function.

关 键 词：树突状细胞 细胞因子诱导的杀伤细胞 放疗 化疗 1 25-二羟维生素D3 

分 类 号：R734.2[医药卫生—肿瘤]